Global Ganja Report

A ground-breaking study is set to begin in Australia, to determine if cannabis can improve the quality of life of those suffering from dementia. Elderly care facilities are watching closely, hoping cannabis will prove a key to help those they look after lead happier lives, with less medication.

Recent years have seen breakthroughs in research into cannabis as a possible treatment for dementia. Now clinical studies on patients are about to get underway at an Australia university, to track changes in actual patients.

The study is to be led by the Institute for Health Research at the University of Notre Dame in Perth. As Australia's 7News reports, the research team is currently screening candidates for the study, which will use lab-grown cannabis from Slovenia. The researchers are especially hoping the CBD-heavy strain will reduce the most deleterious and troubling effects of dementia.

The cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. The spray will be produced by MGC Pharmaceuticals, an Australian firm founded by Israeli researchers.

The clinical trial will be held over a 14 month period starting early next year. It will involve 50 participants aged 65 years and older who have mild dementia and who currently live in an accredited residential aged-care facility.

Study leader Amanda Timler told the West Australian newspaper she believes that cannabis "works well with a lot behavioural and neuro-psychotic symptoms associated with dementia, such as aggression and agitation. Medicinal cannabis is also thought to increase appetite as well as improve sleep cycles."

She added to Australia's morning TV news show Sunrise: "We think cannabis is going to help ameliorate behavioural signs and symptoms we see from dementia. It's one of those medications that will treat a number of symptoms compared with typically being diagnosed with dementia and taking a number of different drugs."

Mechanism found in brain
The Australia study is following up on laboratory work that has proved very promising for the efficacy of cannabinoids in this regard.

The most significant breakthrough was reported in a study issued in November 2017 by the Salk Institute for Biological Studies in La Jolla, Calif. The Institute's Dr. David Schubert led a team that grew nerve cells taken from a human brain, to examine factors that influence levels of a toxic protein linked to Alzheimer's disease. The protein, known as amyloid beta, builds up within neurons, inflaming and eventually killing them. The team exposed the neurons to cannabis—finding that it cleared away the protein, reduced inflammation, and allowed the brain cells to survive. 

The findings won scant media attention, but the medical community definitely took note. "It's a very important discovery," Dr. Michael Weiner, who oversees Alzheimer's research at the San Francisco VA Medical Center, told local KPIX.

The KPIX account also profiled some Bay Area seniors who reported dramatic improvement—mostly under administration of CBD extracts.

Earlier in 2017, a study by scientists at the University of Bonn in Germany, published in the journal Nature Medicine, found that aging mice administered daily small doses of THC actually underwent a reversal of cognitive decline. This was determined by their improved performance on cognitive tasks, such as finding their way though a maze. The researchers said they anticipated potential cannabis-based treatments for dementia on the basis of the results. "If we can rejuvenate the brain so that everybody gets five to 10 more years without needing extra care then that is more than we could have imagined," said study leader Andras Bilkei-Gorzo.

US bureaucracy starting to bend?
In two years, those behavioral findings on lab mice have advanced to the actual identification of a dementia-fighting mechanism in the human brain, and now to actual clinical trials on human patients. But it is significant that the clinical trials are taking place overseas. Cannabis research in the US continues to be bottlenecked by federal prohibition.

There are some tentative glimmers of hope for an opening on the cannabis research front in the United States. The Drug Enforcement Administration in August announced plans to expand permitted cannabis research, and acknowledged that CBD is in fact now legal, pursuant to passage of the 2018 Farm Bill.

As Politico reports, later that month the National Institutes of Health and the Food & Drug Administration, in a letter responding to a query by Sen. Brian Schatz (D-HI), stated: "NIH and FDA strongly support the need for additional research on cannabis and constituent compounds... The continued placement of marijuana in Schedule I of the Controlled Substances Act creates significant administrative and cost challenges that slow this research and may deter scientists from pursuing cannabis research altogether... To address these challenges, NIH and FDA recommend streamlining the process for conducting research with cannabis and other Schedule I substances."

This kind of change is long overdue. The bizarre contradiction of federal policy is exemplified by the fact that in 2003, the US Department of Health & Human Services secured a patent—number 6630507—for the use of cannabinoids as antoxidants and neuroprotectants. The patent describes potential efficacy against both cancer and degenerative diseases, including dementia. Yet just three years later, an FDA memorandum reiterated the official position that cannabis has "no medical value."
 
Cross-post to Cannabis Now

Image of THC molecule via Schaffer Library of Drug Policy

Follow @GlobalGanjaRpt